{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:42Z","timestamp":1790701542502,"version":"4.1.0"},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Regional Health Authority"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2020-0141_abs_001_w2aab3b7b2b1b6b1aab1c15b1Aa\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Hyperthermic intraperitoneal chemotherapy (HIPEC) is a beneficial surgical technique for patients, but the surgeons are being exposed to cytotoxic drugs. Few biomonitoring studies were led on blood samples in the context of HIPEC. This study aimed to evaluate the surgeon\u2019s plasmatic and red blood cell (RBC) contamination by irinotecan, two of its major metabolites and platinum compounds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0141_abs_002_w2aab3b7b2b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HIPEC procedures performed using the coliseum techniques were observed between September 2015 and April 2018 in a French comprehensive cancer center. Irinotecan and its metabolites SN-38 and APC were dosed by UHPLC with a limit of quantification determined at 50\u00a0pg\/mL. Platinum compounds were dosed by inductively coupled plasma mass spectrometry with a limit of quantification determined at 16\u00a0pg\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0141_abs_003_w2aab3b7b2b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite collective and personal protective equipment, 80% of plasma samples were contaminated by irinotecan and 33% by platinum compounds out of 21. The results showed that the surgeon was contaminated after HIPEC and even after a period of HIPEC inactivity. Nineteen percent of plasmatic samples and 45% of RBC samples were contaminated by SN-38, the active metabolite of irinotecan. APC was only found in some RBC samples (33%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0141_abs_004_w2aab3b7b2b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even if this study shows blood contamination by irinotecan, two of its major metabolites (including active SN-38) and platinum compounds both in the plasma and RBC of a surgeon performing the HIPEC procedures, further studies should be performed to confirm these results. Additional studies should be carried out to further investigate the contamination in the context of HIPEC and more broadly in the hospital.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2020-0141","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T23:10:28Z","timestamp":1614985828000},"page":"49-55","source":"Crossref","is-referenced-by-count":10,"title":["Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds?"],"prefix":"10.1515","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-6539","authenticated-orcid":false,"given":"Guillaume","family":"Saint-Lorant","sequence":"first","affiliation":[{"name":"Normandie Univ, UNICAEN, ABTE , Caen , France"},{"name":"Department of Pharmacy , CHU de Caen , Caen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rodier","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, ABTE , Caen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Guilloit","sequence":"additional","affiliation":[{"name":"Department of Surgery , Comprehensive Cancer Center F. Baclesse , Caen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ndaw","sequence":"additional","affiliation":[{"name":"Toxicology and Biomonitoring Department , INRS , Vandoeuvre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Melczer","sequence":"additional","affiliation":[{"name":"Toxicology and Biomonitoring Department , INRS , Vandoeuvre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Lagadu","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, ABTE , Caen , France"},{"name":"Comprehensive Cancer Center F. Baclesse , Caen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Palix","sequence":"additional","affiliation":[{"name":"Department of Occupational Health , Comprehensive Cancer Center F. Baclesse , Caen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Del\u00e9p\u00e9e","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, ABTE , Caen , France"},{"name":"Comprehensive Cancer Center F. Baclesse , Caen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"2025120909232259426_j_pp-2020-0141_ref_001_w2aab3b7b2b1b6b1ab2b1b1Aa","unstructured":"Spratt, JS, Adcock, RA, Muskovin, M, Sherrill, W, McKeown, J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Canc Res 1980;40:256\u201360."},{"key":"2025120909232259426_j_pp-2020-0141_ref_002_w2aab3b7b2b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Fujimoto, S, Shrestha, RD, Kokubun, M, Ohta, M, Takahashi, M, Kobayashi, K, et al.. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36\u201341.","DOI":"10.1097\/00000658-198807000-00005"},{"key":"2025120909232259426_j_pp-2020-0141_ref_003_w2aab3b7b2b1b6b1ab2b1b3Aa","unstructured":"Gilly, FN, Carry, PY, Sayag, AC, Braillon, GB, Volloch, AA, Panteix, GG, et al.. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia with mitomycin C. Initial experience. Ann Chir 1990;44:545\u201351."},{"key":"2025120909232259426_j_pp-2020-0141_ref_004_w2aab3b7b2b1b6b1ab2b1b4Aa","unstructured":"Canbay, E, Yonemura, Y, Brucher, B, Baik, SH, Sugarbaker, PH. Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases. Chin J Canc Res 2014;26:1\u20133."},{"key":"2025120909232259426_j_pp-2020-0141_ref_005_w2aab3b7b2b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Armstrong, DK, Bundy, B, Wenzel, L, Huang, HQ, Baergen, R, Lele, S, Gynecologic Oncology Group, et al.. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34\u201343.","DOI":"10.1056\/NEJMoa052985"},{"key":"2025120909232259426_j_pp-2020-0141_ref_006_w2aab3b7b2b1b6b1ab2b1b6Aa","unstructured":"Sugarbaker, P. Technical handbook for the integration of cytoreductive surgery and perioperative intraperitoneal chemotherapy into the surgical managements of gastrointestinal and gynecologic malignancy, 4th ed. Michigan: The Ludann Company Grand Rapids; 2005."},{"key":"2025120909232259426_j_pp-2020-0141_ref_007_w2aab3b7b2b1b6b1ab2b1b7Aa","unstructured":"Elias, D, Antoun, S, Goharin, A, Otmany, AE, Puizillout, JM, Lasser, P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest 2000;1:431\u20139."},{"key":"2025120909232259426_j_pp-2020-0141_ref_008_w2aab3b7b2b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Ortega-Deballon, P, Facy, O, Jambet, S, Magnin, G, Cotte, E, Beltramo, JL, et al.. Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol 2010;17:1957\u201363.","DOI":"10.1245\/s10434-010-0937-z"},{"key":"2025120909232259426_j_pp-2020-0141_ref_009_w2aab3b7b2b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Halkia, E, Tsochrinis, A, Vassiliadou, DT, Pavlakou, A, Vaxevanidou, A, Datsis, A, et al.. Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol 2015;2015:610597.","DOI":"10.1155\/2015\/610597"},{"key":"2025120909232259426_j_pp-2020-0141_ref_010_w2aab3b7b2b1b6b1ab2b1c10Aa","unstructured":"Rajeev, R, Klooster, B, Turaga, KK. Impact of surgical volume of centers on postoperative outcomes from cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion. J Gastrointest Oncol 2016;7:122\u20138."},{"key":"2025120909232259426_j_pp-2020-0141_ref_011_w2aab3b7b2b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Elias, D, Goere, D, Blot, F, Billard, V, Pocard, M, Kohneh-Shahri, N, et al.. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compee cytoreductive surgery : mortality and morbidity in 106 consecutive patients. Ann Surg Oncol 2007;14:1818\u201324.","DOI":"10.1245\/s10434-007-9348-1"},{"key":"2025120909232259426_j_pp-2020-0141_ref_012_w2aab3b7b2b1b6b1ab2b1c12Aa","unstructured":"de Bree, E. Optimal drugs for HIPEC in different tumors. J Buon 2015;20(1 Suppl):S40\u20136."},{"key":"2025120909232259426_j_pp-2020-0141_ref_013_w2aab3b7b2b1b6b1ab2b1c13Aa","unstructured":"Goodman, MD, McPartland, S, Detelich, D, Saif, MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol 2016;7:45\u20137."},{"key":"2025120909232259426_j_pp-2020-0141_ref_014_w2aab3b7b2b1b6b1ab2b1c14Aa","unstructured":"Irinotecan, USP. Volume 1. Drug Information for the Health care professional, Th ed. Englewood, Colorado: Micromedex, Inc; 2000."},{"key":"2025120909232259426_j_pp-2020-0141_ref_015_w2aab3b7b2b1b6b1ab2b1c15Aa","unstructured":"Rothenberg, ML, Kuhn, JG, Schaaf, LJ, Drengler, RL, Eckhart, SG, Villalona-Calero, MA, et al.. Alternative dosing schedules for irinotecan. Oncology 1998;12(8 Suppl 6):68\u201371."},{"key":"2025120909232259426_j_pp-2020-0141_ref_016_w2aab3b7b2b1b6b1ab2b1c16Aa","unstructured":"Misset, JL, Allain, P. Pharmacokinetics, urinary, and fecal excretion of oxaliplatin in cancer patients. Debiopharm Sanofi Report No. TDR 3500 1995;42."},{"key":"2025120909232259426_j_pp-2020-0141_ref_017_w2aab3b7b2b1b6b1ab2b1c17Aa","unstructured":"Allen, J, Graham, MA, Firth, J, Woolfrey, S, Greenslade, D, Morrison, JG, et al.. Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer. Proc Am Assoc Cancer Res 1998;39:159."},{"key":"2025120909232259426_j_pp-2020-0141_ref_018_w2aab3b7b2b1b6b1ab2b1c18Aa","unstructured":"Kern, W, Braess, J, B\u00f6ttger, B, Kaufmann, CC, Hiddemann, W, Schleyer, E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Canc Res 1999;5:761\u20135."},{"key":"2025120909232259426_j_pp-2020-0141_ref_019_w2aab3b7b2b1b6b1ab2b1c19Aa","unstructured":"Graham, MA, Lockwood, GF, Greenslade, D, Brienza, S, Bayssas, M, Gamelin, E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Canc Res 2000;6:1205\u201318."},{"key":"2025120909232259426_j_pp-2020-0141_ref_020_w2aab3b7b2b1b6b1ab2b1c20Aa","unstructured":"Calvert, H, Judson, I, van der Vijgh, WJ. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Canc Surv 1993;17:189\u2013217."},{"key":"2025120909232259426_j_pp-2020-0141_ref_021_w2aab3b7b2b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Takano, T, Suzuki, S, Tsukiyama, I, Saito, H. A smear method for measuring anti-cancer drugs residues in hospitals. Sangyo Eiseigaku Zasshi 2015;57:275\u201385.","DOI":"10.1539\/sangyoeisei.B15004"},{"key":"2025120909232259426_j_pp-2020-0141_ref_022_w2aab3b7b2b1b6b1ab2b1c22Aa","unstructured":"Mart\u00edn Lancharro, P, De Castro-Acu\u00f1a Iglesias, N, Gonz\u00e1lez-Barcala, FJ, Moure Gonz\u00e1lez, JD. Evidence of exposure to cytostatic drugs in healthcare staff: a review of recent literature. Farm Hosp 2016;40:604\u201321."},{"key":"2025120909232259426_j_pp-2020-0141_ref_023_w2aab3b7b2b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Chauchat, L, Tanguay, C, Caron, NJ, Gagn\u00e9, S, Labr\u00e8che, F, Bussi\u00e8res, JF. Surface contamination with ten antineoplastic drugs in 83 Canadian centers. J Oncol Pharm Pract 2019;25:1089\u201398.","DOI":"10.1177\/1078155218773862"},{"key":"2025120909232259426_j_pp-2020-0141_ref_024_w2aab3b7b2b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Falck, K, Gr\u00f6hn, P, Sorsa, M, Vainio, H, Heinonen, E, Holsti, LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979;1:1250\u20131.","DOI":"10.1016\/S0140-6736(79)91939-1"},{"key":"2025120909232259426_j_pp-2020-0141_ref_025_w2aab3b7b2b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Sessink, PJ, Boer, KA, Scheefhals, AP, Anzion, RB, Bos, RP. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992;64:105\u201312.","DOI":"10.1007\/BF00381477"},{"key":"2025120909232259426_j_pp-2020-0141_ref_026_w2aab3b7b2b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Turci, R, Sottani, C, Spagnoli, G, Minoia, C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci 2003;789:169\u2013209.","DOI":"10.1016\/S1570-0232(03)00100-4"},{"key":"2025120909232259426_j_pp-2020-0141_ref_027_w2aab3b7b2b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Rodier, S, Saint-Lorant, G, Guilloit, JM, Palix, A, Divanon, F, Sichel, F, et al.. Is hyperthermic intraperitoneal chemotherapy (HIPEC) safe for healthcare workers? Surg Oncol 2017;26:242\u201351.","DOI":"10.1016\/j.suronc.2017.04.001"},{"key":"2025120909232259426_j_pp-2020-0141_ref_028_w2aab3b7b2b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Nygren, O, Lundgren, C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health 1997;70:209\u201314.","DOI":"10.1007\/s004200050209"},{"key":"2025120909232259426_j_pp-2020-0141_ref_029_w2aab3b7b2b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Peritonectomy procedures. Canc Treat Res 2007;134:247\u201364.","DOI":"10.1007\/978-0-387-48993-3_15"},{"key":"2025120909232259426_j_pp-2020-0141_ref_030_w2aab3b7b2b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Canc Treat Res 1996;81:149\u201368.","DOI":"10.1007\/978-1-4613-1245-1_13"},{"key":"2025120909232259426_j_pp-2020-0141_ref_031_w2aab3b7b2b1b6b1ab2b1c31Aa","unstructured":"European Medicines Agency (EMA). Committee for medicinal products for human use (CHMP). London, United Kingdom: Guideline on Bioanalytical Method Validation; 2011."},{"key":"2025120909232259426_j_pp-2020-0141_ref_032_w2aab3b7b2b1b6b1ab2b1c32Aa","unstructured":"Food and Drug Administration. FDA guidance for industry: bioanalytical method validation. USA: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2018."},{"key":"2025120909232259426_j_pp-2020-0141_ref_033_w2aab3b7b2b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Schmid, K, Boettcher, MI, Pelz, JOW, Meyer, T, Korinth, G, Angerer, J, et al.. Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C. Eur J Surg Oncol 2006;32:1222\u20135.","DOI":"10.1016\/j.ejso.2006.05.011"},{"key":"2025120909232259426_j_pp-2020-0141_ref_034_w2aab3b7b2b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Izzo, V, Charlier, B, Bloise, E, Pingeon, M, Romano, M, Finelli, A, et al.. UHPLC-MS\/MS-based method for the simultaneous monitoring of eight antiblastic drugs in plasma and urine of exposed healthcare workers. J Pharmaceut Biomed Anal 2018;154:245\u201351.","DOI":"10.1016\/j.jpba.2018.03.024"},{"key":"2025120909232259426_j_pp-2020-0141_ref_035_w2aab3b7b2b1b6b1ab2b1c35Aa","unstructured":"National Institute for Occupational Safety and Health, Centres for Disease Control and Prevention. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings; 2004. Available from: www.cdc.gov\/niosh\/docs\/2004-165\/default.html."},{"key":"2025120909232259426_j_pp-2020-0141_ref_036_w2aab3b7b2b1b6b1ab2b1c36Aa","unstructured":"International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract 2007;13:1\u201381."},{"key":"2025120909232259426_j_pp-2020-0141_ref_037_w2aab3b7b2b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Combes, O, Barr\u00e9, J, Duch\u00e9, JC, Vernillet, L, Archimbaud, Y, Marietta, MP, et al.. In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood. Invest New Drugs 2000;18:1\u20135.","DOI":"10.1023\/A:1006379730137"},{"key":"2025120909232259426_j_pp-2020-0141_ref_038_w2aab3b7b2b1b6b1ab2b1c38Aa","unstructured":"Ndaw, S, Denis, F, Marsan, P, R\u00e9my, A, Robert, A. Exposition professionnelle des personnels de sant\u00e9 hospitaliers aux m\u00e9dicaments cytotoxiques. R\u00e9f\u00e9rences en Sant\u00e9 au Travail 2018;154:81\u201392."},{"key":"2025120909232259426_j_pp-2020-0141_ref_039_w2aab3b7b2b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Konate, A, Poupon, J, Villa, A, Garnier, R, Hasni-Pichard, H, Mezzaroba, D, et al.. Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure. J Surg Oncol 2011;103:6\u20139.","DOI":"10.1002\/jso.21740"},{"key":"2025120909232259426_j_pp-2020-0141_ref_040_w2aab3b7b2b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Villa, AF, El Balkhi, S, Aboura, R, Sageot, H, Hasni-Pichard, H, Pocard, M, et al.. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health 2015;53:28\u201337.","DOI":"10.2486\/indhealth.2014-0025"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0141\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0141\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:59:55Z","timestamp":1765277995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0141\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,3,24]]},"published-print":{"date-parts":[[2021,6,8]]}},"alternative-id":["10.1515\/pp-2020-0141"],"URL":"https:\/\/doi.org\/10.1515\/pp-2020-0141","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,3]]}}}